Cliantha Research Ltd.

Cliantha Research Ltd. is a full-service Clinical Research Organization (CRO) providing comprehensive clinical research services, including clinical trial management, bioequivalence studies, and regulatory consulting, to enhance drug development processes. Founded in 2004 and headquartered in Ahmedabad, India, Cliantha Research Ltd. specializes in clinical research services.

Notably, the company operates independently without any mention of subsidiaries or parent companies. The CEO, Vijay Patel, drives the company’s strategic direction, leveraging his extensive experience in the healthcare sector. Cliantha Research operates as a full-service Clinical Research Organization (CRO) specializing in a comprehensive array of clinical research services. The company’s core product offerings encompass clinical trial management, bioequivalence studies, and regulatory consulting, which are designed to facilitate the drug development process from inception to completion.

These services are aimed at addressing the complexities of clinical trials, ensuring compliance with regulatory standards, and enhancing the efficiency of bringing new therapeutics to market. Cliantha serves a diverse clientele that includes pharmaceutical and biotechnology companies across North America, Europe, and Asia. By delivering these services with a strong emphasis on scientific integrity, Cliantha Research builds robust partnerships that cater to both emerging and established organizations in the healthcare sector seeking to conduct clinical studies. In the year 2023, Cliantha Research reported a revenue of USD 69.

74 mn, with an EBITDA of USD 17. 61 mn. Revenue is primarily derived from contractual agreements for clinical trial management and consulting services, structured as fee-for-service models or project-based pricing, with different tiers based on the complexity and scope of individual projects. Cliantha Research is focused on expanding its service offerings and geographic reach.

Plans include launching new products aimed at enhancing clinical trial efficiency by 2024. The company is also targeting expansion into markets in Europe and North America to increase its global footprint. Recent funding will be utilized to support these initiatives, enhancing operational capabilities and facilitating entry into new regions.